Endothelial Progenitor Cells and NADPH Oxidase Enzyme Activity in the Development of an Aortic Aneurysm.

Dihydrorhodamine 123 Disease Progression Endothelial Progenitor Cells Flow Cytometry Thoracic Aortic Aneurysms

Journal

Brazilian journal of cardiovascular surgery
ISSN: 1678-9741
Titre abrégé: Braz J Cardiovasc Surg
Pays: Brazil
ID NLM: 101677045

Informations de publication

Date de publication:
16 08 2022
Historique:
pubmed: 25 1 2022
medline: 20 8 2022
entrez: 24 1 2022
Statut: epublish

Résumé

Endothelial progenitor cells (EPCs) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme activity may affect the vessel wall and have a role in development of aortic aneurysms. EPCs originate from hematopoietic stem cells and can be enumerated from peripheral blood samples by flow cytometry. In this study, we aimed to evaluate the relation of EPC number and NADPH oxidase enzyme activity in the development of thoracic aortic aneurysm (TAA). Patients with TAA (n=30) and healthy individuals without TAA (control, n=10) were included in our study. Characterization and enumeration of EPC from peripheral blood samples were performed by flow cytometry with panels including markers of EPCs (CD34/CD133/CD309/CD146/CD144). Additionally, NADPH oxidase enzyme activity (capacity) was also measured by the dihydrorhodamine 123 (DHR 123) test. The enumeration of EPC with CD34+/CD146+ marker showed that the number of mean EPC/106 cells was increased in the patient group (41.5/106 cells), but not in the control group (20.50/105 cells) (P<0.01). Additionally, patients with TAA presented significantly lower NADPH oxidase activity by DHR assay than healthy controls (mean stimulation index: 60.40± 7.86 and 75.10±5.21, respectively) (P<0.01). Our results showed that the number of EPCs is significantly higher in aortic aneurysm patients and may have a role in disease progression. The crosstalk between NADPH oxidase enzyme capacity and EPC number may be useful as a parameter to explain the clinical progression of TAA.

Identifiants

pubmed: 35072395
doi: 10.21470/1678-9741-2020-0458
pmc: PMC9423793
doi:

Substances chimiques

Antigens, CD34 0
Biomarkers 0
CD146 Antigen 0
NADPH Oxidases EC 1.6.3.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

501-510

Références

Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1916-21
pubmed: 15319272
Circ Res. 2006 Feb 17;98(3):e20-5
pubmed: 16439688
Int J Cardiol. 2013 Oct 3;168(3):2389-96
pubmed: 23506637
FASEB J. 2019 Jan;33(1):885-895
pubmed: 30351992
Circulation. 1994 Nov;90(5 Pt 2):II224-7
pubmed: 7955258
Eur J Cardiothorac Surg. 2011 Jul;40(1):e6-12
pubmed: 21481600
Eur J Vasc Endovasc Surg. 2018 Jul;56(1):102-109
pubmed: 29703523
J Allergy Clin Immunol. 2013 Nov;132(5):1156-1163.e5
pubmed: 23910690
Metab Brain Dis. 2018 Feb;33(1):293-299
pubmed: 29209923
Free Radic Biol Med. 2008 Nov 1;45(9):1340-51
pubmed: 18760347
Circulation. 2002 Jun 25;105(25):3017-24
pubmed: 12081997
Exp Clin Cardiol. 2011 Spring;16(1):11-5
pubmed: 21523201
Circulation. 1998 Jul 21;98(3):193-5
pubmed: 9697816
Int J Mol Sci. 2020 Oct 16;21(20):
pubmed: 33081376
Atherosclerosis. 2009 Jan;202(1):128-34
pubmed: 18502427
Ann Vasc Surg. 1991 May;5(3):229-33
pubmed: 2064915
J Vasc Surg. 2012 Jul;56(1):45-52
pubmed: 22551908
Curr Med Chem. 2020;27(7):1081-1088
pubmed: 31549591
Radiologe. 2001 Aug;41(8):624-32
pubmed: 11552376
Blood. 2001 Dec 15;98(13):3677-84
pubmed: 11739172
Circulation. 2003 Nov 25;108(21):2710-5
pubmed: 14597586
Eur J Clin Invest. 2006 Apr;36(4):257-64
pubmed: 16620288
Microbes Infect. 2003 Nov;5(14):1307-15
pubmed: 14613774
Arterioscler Thromb Vasc Biol. 2006 May;26(5):987-94
pubmed: 16497993
Tissue Eng. 2006 Feb;12(2):331-5
pubmed: 16548691

Auteurs

Bilge Bingol (B)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Deniz Elcik (D)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Sinan Kutuk (S)

Department of Immunology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Sevil Özsoy (S)

Department of Immunology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Saban Kelesoglu (S)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Aydin Tuncay (A)

Department of Cardiovascular Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Zeki Cetinkaya (Z)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Joma Sulaiman (J)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Mehmet Tugrul Inanc (MT)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Nihat Kalay (N)

Department of Cardiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Mustafa Yavuz Koker (MY)

Department of Immunology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH